Search Results - "Mossaheb, N."

Psychotic-like experiences in non-clinical subgroups with and without specific beliefs by Hinterbuchinger, B, Koch, M, Trimmel, M, Litvan, Z, Baumgartner, J, Meyer, E L, Friedrich, F, Mossaheb, N

“…Assuming a transdiagnostic and extended psychosis phenotype, psychotic-like experiences (PLEs) and psychotic symptoms are on a phenomenological and temporal…”
Get full text

Correction to: Psychotic-like experiences in non-clinical subgroups with and without specific beliefs by Hinterbuchinger, B, Koch, M, Trimmel, M, Litvan, Z, Baumgartner, J, Meyer, E L, Friedrich, F, Mossaheb, N

Get full text

Personality Functioning and Self-Disorders in different stages of Psychotic Disorders and Borderline Personality Disorder by Gruber, M., Alexopoulos, J., Feichtinger, K., Parth, K., Wininger, A., Mossaheb, N., Friedrich, F., Litvan, Z., Hinterbuchinger, B., Doering, S., Blüml, V.

“…Introduction Personality functioning, self-disorders and their relationship to psychotic symptoms on a continuum from mild attenuated experiences to manifest…”
Get full text

The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo by McHugh, M.J., McGorry, P.D., Yuen, H.P., Hickie, I.B., Thompson, A., de Haan, L., Mossaheb, N., Smesny, S., Lin, A., Markulev, C., Schloegelhofer, M., Wood, S.J., Nieman, D., Hartmann, J.A., Nordentoft, M., Schäfer, M., Amminger, G.P., Yung, A, Nelson, B.

“…Individuals are considered Ultra-High-Risk (UHR) for psychosis if they meet a set of standardised criteria including presumed genetic vulnerability (Trait), or…”
Get full text

Dynamic prediction of transition to psychosis using joint modelling by Yuen, H.P., Mackinnon, A., Hartmann, J., Amminger, G.P., Markulev, C., Lavoie, S., Schäfer, M.R., Polari, A., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I.B., Berger, G., Chen, E.Y.H., de Haan, L., Nieman, D.H., Nordentoft, M., Riecher-Rössler, A., Verma, S., Thompson, A., Yung, A.R., McGorry, P.D., Nelson, B.

“…Considerable research has been conducted seeking risk factors and constructing prediction models for transition to psychosis in individuals at ultra-high risk…”
Get full text

Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes by Youn, S., Phillips, L.J., Amminger, G.P., Berger, G., Chen, E.Y.H., de Haan, L., Hartmann, J.A., Hickie, I.B., Lavoie, S., Markulev, C., McGorry, P.D., Mossaheb, N., Nieman, D.H., Nordentoft, M., Riecher-Rössler, A., Schäfer, M.R., Schlögelhofer, M., Smesny, S., Thompson, A., Verma, S., Yuen, H.P., Yung, A.R., Nelson, B.

“…There has been limited research into the predictive value of basic symptoms and their relationship with other psychopathology in patients identified using the…”
Get full text

Do schizotypal or borderline personality disorders predict onset of psychotic disorder or persistent attenuated psychotic symptoms in patients at high clinical risk? by Hadar, H., Zhang, H., Phillips, L.J., Amminger, G.P., Berger, G.E., Chen, E.Y.H., de Haan, L., Hartmann, J.A., Hickie, I.B., Lavoie, S., Markulev, C., McGorry, P.D., Mossaheb, N., Nieman, D.H., Nordentoft, M., Riecher-Rössler, A., Schäfer, M.R., Schlögelhofer, M., Smesny, S., Thompson, A., Verma, S., Yuen, H.P., Yung, A.R., Nelson, B.

Get full text

In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram by KLEIN, N, SACHER, J, DUDCZAK, R, TAUSCHER, J, KASPER, S, GEISS-GRANADIA, T, ATTARBASCHI, T, MOSSAHEB, N, LANZENBERGER, R, PÖTZI, C, HOLIK, A, SPINDELEGGER, C, ASENBAUM, S

“…Escitalopram is a dual serotonin reuptake inhibitor (SSRI) approved for the treatment of depression and anxiety disorders. It is the S-enantiomer of…”
Get full text

S21-04 - Fatty acid metabolism and the onset of psychotic disorder by Amminger, P, Mossaheb, N, Schlögelhofer, M, Schäfer, M

“…Introduction Potentially chronic diseases often have a critical point in their course beyond which treatment becomes less effective. In support of this, early…”
Get full text

AS33-01 - Natural lithium in drinking water and suicide mortality by Kapusta, N, Mossaheb, N, Etzersdorfer, E, Thau, K, Willeit, M, Praschak-Rieder, N, Sonneck, G, Leithner-Dziubas, K

“…Background There is evidence that natural levels of lithium in drinking water may have a protective effect on suicide mortality. Aims To evaluate the…”
Get full text

P03-289 - Association of deficits in smell identification, social and basic cognition in patients with schizophrenia-spectrum disorders, their first-degree relatives and matched healthy controls by Mossaheb, N, Schloegelhofer, M, Kaufmann, R.M, Aninilkumparambil, T, Gold, A, Himmelbauer, C, Inreiter, S, Schlehaider, L, Hoffmann, H, Aschauer, H.N

“…Introduction Associations between smell identification deficits (SID) and impairments in basic cognitive domains have been shown in patients with…”
Get full text

P03-247 - Sex-related differences in smell identification in patients with schizophrenia, their first-degree relatives and matched healthy controls by Kaufmann, R.M, Mossaheb, N, Schlögelhofer, M, Aninilkumparambil, T, Gold, A, Himmelbauer, C, Inreiter, S, Schlehaider, L, Aschauer, H.N

“…Introduction Sex-related differences in smell identification have been shown in healthy subjects, however, in patients with schizophrenia these findings are…”
Get full text

P.3.b.003 Comprehension of metaphors in patients with schizophrenia by Mossaheb, N, Aschauer, H.N, Pils, N, Raab, M, Willinger, U

Get full text

NEURAPRO: a multi-centre RCT of omega-3 polyunsaturated fatty acids versus placebo in young people at ultra-high risk of psychotic disorders—medium-term follow-up and clinical course by Nelson, B., Amminger, G. P., Yuen, H. P., Markulev, C., Lavoie, S., Schäfer, M. R., Hartmann, J. A., Mossaheb, N., Schlögelhofer, M., Smesny, S., Hickie, I. B., Berger, G., Chen, E. Y. H., de Haan, L., Nieman, D. H., Nordentoft, M., Riecher-Rössler, A., Verma, S., Thompson, A., Yung, A. R., McGorry, P. D.

“…This study reports a medium-term follow-up of a randomised, double-blind, placebo-controlled trial of omega-3 polyunsaturated fatty acids (PUFA) in ultra-high…”
Get full text

Emotion recognition in individuals at clinical high-risk for schizophrenia by Amminger, G Paul, Schäfer, Miriam R, Papageorgiou, Konstantinos, Klier, Claudia M, Schlögelhofer, Monika, Mossaheb, Nilufar, Werneck-Rohrer, Sonja, Nelson, Barnaby, McGorry, Patrick D

“…Problems in the perception of emotional material, in particular deficits in the recognition of negative stimuli, have been demonstrated in schizophrenia…”
Get full text

Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder by Lanzenberger, Rupert R, Mitterhauser, Markus, Spindelegger, Christoph, Wadsak, Wolfgang, Klein, Nikolas, Mien, Leonhard-Key, Holik, Alexander, Attarbaschi, Trawat, Mossaheb, Nilufar, Sacher, Julia, Geiss-Granadia, Thomas, Kletter, Kurt, Kasper, Siegfried, Tauscher, Johannes

“…Background Results from studies in serotonin-1A (5-HT1A ) knockout mice and previous positron emission tomography (PET) studies in humans imply a role for…”
Get full text

Role of aripiprazole in treatment-resistant schizophrenia by Mossaheb, Nilufar, Kaufmann, Rainer M

“…About one third of patients with schizophrenia respond unsatisfactorily to antipsychotic treatment and are termed "treatment-resistant". Clozapine is still the…”
Get full text

Fatty acid metabolism and the onset of psychotic disorder by Amminger, P., Mossaheb, N., Schlögelhofer, M., Schäfer, M.

“…Introduction Potentially chronic diseases often have a critical point in their course beyond which treatment becomes less effective. In support of this, early…”
Get full text

Distress related to attenuated psychotic symptoms: Static and dynamic association with transition to psychosis, non-remission and transdiagnostic symptomatology in clinical high-risk patients in an international intervention trial by Nelson, B, Yuen, H P, Amminger, G P, Berger, G, Chen, E Y H, de Haan, L, Hartmann, J A, Hickie, I B, Lavoie, S, Markulev, C, Mossaheb, N, Nieman, D H, Nordentoft, M, Polari, A, Riecher-Rössler, A, Schäfer, M R, Schlögelhofer, M, Smesny, S, Tedja, A, Thompson, A, Verma, S, Yung, A R, McGorry, P D

“…This study examined whether distress in relation to attenuated psychotic symptoms (DAPS) is associated with clinical outcomes in an ultra-high-risk (UHR) for…”
Get full text

Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram by Kasper, Siegfried, Sacher, Julia, Klein, Nikolas, Mossaheb, Nilufar, Attarbaschi-Steiner, Trawat, Lanzenberger, Rupert, Spindelegger, Christoph, Asenbaum, Susanne, Holik, Alexander, Dudczak, Robert

“…Escitalopram the S-enantiomer of the racemate citalopram, is clinically more effective than citalopram in the treatment of major depressive disorder. However,…”
Get full text